Evidence map›Paper›PMID 34735626›Full record

ReviewCurrent diabetes reports2021

Assessing Glycemic Control Using CGM for Women with Diabetes in Pregnancy.

Grenye O'Malley, Ally Wang, Selassie Ogyaadu, Carol J Levy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grenye O'MalleyIcahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA. omallg01@mssm.edu.ORCID http://orcid.org/0000-0001-7940-2624
Ally WangIcahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA.
Selassie OgyaaduIcahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA.
Carol J LevyIcahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA. carol.levy@mssm.edu.ORCID http://orcid.org/0000-0002-3492-2578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDiabetes during pregnancy increases the risk of maternal and fetal complications. This article reviews the types of CGM currently available, the glucose metrics which correlate with pregnancy outcomes, endocrine organization recommendations, clinical considerations for CGM implementation, and anticipated directions for future research. RECENT

findingsCGM use during pregnancy is increasing, and recommendations for use have been incorporated into many organizations' consensus guidelines. Increased time spent within a target range of 63-140 mg/dL and lower mean glucose are associated with lower risk of neonatal complications including large for gestational age infants. Use of CGM during pregnancy can detect postprandial and nocturnal hyperglycemia missed by self-monitoring of blood glucose (SMBG) which can be used for prognosis and to guide pharmacologic interventions. The use of continuous glucose monitoring (CGM) during pregnancies complicated by type 1, type 2, and gestational diabetes has been shown to improve outcomes.

Indexed as

Diabetes, GestationalDiabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringFemaleGlycemic ControlHumansInfant, NewbornPregnancyBlood GlucoseContinuous glucose monitoringGestationalPregnancySensor

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.